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nzyme Inhibitor as a Marker, Not
Risk Factor, for Poor Prognosis
he recent paper by Miceli et al. (1) showed that, compared with
hose not receiving angiotensin-converting enzyme inhibitor
ACEI) therapy, patients receiving ACEI therapy had a significant
hort-term risk of in-hospital death, renal dysfunction, and atrial
brillation when they underwent a coronary artery bypass grafting.
ropensity score matching was applied to control confounding
actors that differed between ACEI and non-ACEI patients in this
bservational cohort study. However, 2 epidemiological issues
hould be mentioned here. First, potential bias from uncontrolled
onfounding may arise when ACEI use itself is a marker for a
ondition with a poor prognosis that will trigger clinicians to use
CEI therapy. Consequently, ACEI therapy is found to be
ssociated with an increased risk of the outcome, as this study
howed. The bias cannot be easily handled by propensity score
atching, which included only known clinical measures. Second,
n accelerated failure time model is more suitable for analyzing the
hort-term outcome data than a proportional hazards model and
onditional logistic regression model due to a short follow-up
eriod. The authors should provide detailed person-time data and
heck the assumption of proportional hazard for ACEI use.
escriptive statistics, including survival curve plotting and tabula-
ion, may be helpful for readers to understand the clinical scenario.
time-dependent covariate model may be incorporated for
djusting ACEI use and clinical parameters.
Clinical observational studies provide scientific knowledge that
hould be tested in a randomized, controlled trial setting in which
onfounding and bias are controlled. Therefore, before searching
he biological and clinical meanings of ACEI’s effect on the risk of
hort-term prognosis among patients undergoing a coronary by-
ass grafting, the authors should first address some basic epide-
iological and methodological issues, including confounding by
ndication and event history data analysis.
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. Miceli A, Capoun R, Fino C, et al. Effects of angiotensin-converting
enzyme inhibitor therapy on clinical outcome in patients undergoing
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he aim of our study was to evaluate the effect of pre-operative
ngiotensin-converting enzyme inhibitor (ACEI) treatment on
arly outcomes after coronary artery bypass grafting (CABG) (1)
y reviewing our prospectively collected institutional database. We
gree that ACEI users were higher-risk patients compared with
on-ACEI users; however, we identified a propensity score–
atched group to perform our analysis. After matching, baseline
haracteristics were well balanced, without any statistical differ-
nce. Propensity scoring is simply a method for reducing the effect
f selection bias and potential confounding in observational studies
hen randomization to treatment groups is not possible, and this
as highlighted as a limitation of our study.
Survival analysis, independent of its nonparametric, semipara-
etric, or parametric methods, is applicable when the measure of
nterest is a time-related event (2). According to the current
merican College of Cardiology/American Heart Association
uidelines for CABG, we defined as early outcomes those events
ccurring during the immediate hospitalization or within 30 days
f surgery (3). For these reasons, our outcomes were considered as
-time events and appropriate statistical methods were applied (4).
Observational studies can provide very valid clinical information (5)
egarding “real-world” patients undergoing CABG and represent the
tarting point for the scientific and clinical knowledge on which
andomized clinical trials are based. We do agree that the “last word”
n confirming whether pre-operative ACEI treatment is a marker or
risk factor of poor early outcomes in patients undergoing CABG
ill come from large sample randomized studies.
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